Daily Archives: April 17, 2021

TheComplementary and Alternative Medicine Marketresearch report thoroughly explains each and every aspect related to the Global Complementary and Alternative Medicine Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.This report introduces manufacturing process analysis, market share of Complementary and Alternative Medicine industry participants, and industry chain structure.

Complementary and Alternative Medicine Market Insight:

Complementary and alternative medicine market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence cancer and other serious diseases worldwide and emerging markets are the factors responsible for the growth of this market.

Avail Free PDF Sample Copy of the Report to Understand the Structure of the Complete Report (Including All Related Graphs & Charts) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-complementary-and-alternative-medicine-market

This Free report sample includes:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Manufacturers covered in this report are:

Nordic Naturals, Natures Bounty, Unity Woods Yoga Center, Columbia Nutritional, First Natural Brands Ltd., Ayush Ayurveda, Sheng Chang Pharmaceutical Company, Pure Encapsulations, LLC. Quantum-Touch, and Herb Pharm, LLC among others.

Competitive landscape:

Competitive analysis was carried out in the report. This competitive analysis provides insightful data about industry market leaders. The purpose is to help customers understand the existing market participants and potential market participants in the industry. The way the report is made allows customers not only to make the right decisions about the industry but also to maintain steady growth in the industry in the long run. The purpose is to guide customers towards the steady development of their industry growth.

This report includes the following deliverable

TheComplementary and Alternative Medicine marketreport provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Complementary and Alternative Medicine market.

Major Regions as Follows:

Get Table Of Contents of This Premium Research For Free @https://www.databridgemarketresearch.com/toc/?dbmr=global-complementary-and-alternative-medicine-market

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

How insights and forecast from the reports could benefit you:

Why choose us:

Table Of Contents: Complementary and Alternative Medicine Market

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Part 07:Five Forces Analysis

Part 08:Market Segmentation

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Part 16:Appendix

If You Have Any Query, Ask Our Experts @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-complementary-and-alternative-medicine-market

Finally,the Complementary and Alternative Medicine Market report is a source of convincing research reports that can accelerate your business exponentially. The report provides the main regional settings, economic conditions, and the value, benefits, restrictions, generation, supply, demand, and market development speed and figures of the project.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

The rest is here:

Complementary and Alternative Medicine Market To Register a Strong Growth Rate and Huge Profits The Courier - The Courier

Trending Report: Complementary And Alternative Medicine Market

The Complementary And Alternative Medicine industry overview, market segment analysis, regional market overview, market defination, limitations, opportunities, industry news and Trends are just some of the topics covered in this report. The report presents the market analysis based on several factors. Different exploratory techniques such as qualitative and quantitative analysis have been used to give data accurately. For a better understanding of the customers, it uses effective graphical presentation techniques, such as graphs, charts, tables as well as pictures.

Request to Get the Sample of the Report: @ https://www.marketresearchinc.com/request-sample.php?id=99194

Major Market Players Profiled in the Global Complementary And Alternative Medicine Market Report include

The insights in the report are easy to understand and include a graphical representation of the numbers in the form of histograms, bar graphs, pie charts, etc. Components such as market drivers, restraints, challenges, and opportunities for the Complementary And Alternative Medicine market are elaborated in detail. It also presents a complete assessment of the anticipated behaviour about the future market and continuously transforming market scenario. Making an informed business decision is a tricky job; this report gives several strategic business methodologies to support you in making those decisions.

Complementary And Alternative Medicine Market Segmentation:

Based on Type

Based on Application

Request a Discount on the report: @ https://www.marketresearchinc.com/ask-for-discount.php?id=99194

Based on Region

North America (NA) US, Canada & Rest of North America

Europe (EU) UK, Germany, France & Rest of Europe

Asia Pacific (APAC) China, Japan, India & Rest of APAC

Latin America (LA) Brazil & Rest of Latin America

Middle East & Africa (MEA) Middle East and Africa

The report provides insights on the following pointers:

Ask any Query about this Report: @ https://www.marketresearchinc.com/enquiry-before-buying.php?id=99194

Some Points from TOC

About Us

Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact Us

Market Research IncAuthor: KevinUS Address: 51 Yerba Buena Lane, Ground Suite,Inner Sunset San Francisco, CA 94103, USACall Us: +1 (628) 225-1818Write Us: sales@marketresearchinc.com

See the article here:

Global Complementary And Alternative Medicine Market Share, Growth, Trends And Forecast To 2028 - The Courier

Whole-genome sequencing was found to provide rapid and accurate genomic profiling for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), and this technology may be a potential replacement for conventional cytogenetic and sequencing approaches to risk stratification, according to the results of a study published in the New England Journal of Medicine.

Implementing whole-genome sequencing for clinical testing can provide a unified, stable, and extensible platform that minimizes laboratory-specific bias and that can be standardized throughout the world, study researchers stated. Although our study focused on myeloid cancers, many of the advantages of whole-genome sequencing that we observed will directly apply to patients with other cancers, the researchers concluded.

Patients who have AML or MDS often undergo genetic profiling for diagnostic classification and risk assessment. This study tested whether whole-genome sequencing could be streamlined and applied to diagnostic clinical samples in real time. The study included genomic profiles from 263 patients with myeloid cancers, including 235 who had undergone cytogenetic analysis.

Continue Reading

In this study, whole-genome sequencing identified all 40 recurrent translocations and 91 copy-number alterations that were detected using cytogenetic analysis. In addition to these mutations, whole-genome sequencing identified new clinically reportable genomic events in 40 of the 235 patients (17%).

Prospective sequencing was performed on samples taken from 117 consecutive patients in a median of 5 days. These 5 days included 2 days for library preparation, 2 days for sequencing, and less than 1 day for analysis. Results provided new genetic information in 29 patients (24.8%), and risk category changed in 19 patients (16.2%).

According to the researchers, risk prediction based on the whole-genome sequencing results correlated with outcomes. Significantly longer overall survival was observed in the 21 patients with intermediate or favorable risk compared with the 6 patients with adverse risk.

This survival difference was superior to that resulting from the assignment of patients to risk groups on the basis of gene mutations alone, the researchers noted. Although larger studies involving more patients will be required to firmly establish the clinical

performance of whole-genome sequencing, our proof-of-concept study shows that this method has the potential to add prognostic value by expanding risk stratification to more patients, especially for those with inconclusive results on cytogenetic analysis, where whole-genome sequencing could have an immediate effect on treatment decisions.

Disclosure: Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Reference

Duncavage EJ, Schroeder MC, OLaughlin M, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021;384:924-935. doi:10.1056/NEJMoa2024534

Go here to read the rest:

Genome Sequencing: An Alternative for Risk Stratification in Myeloid Cancers - Cancer Therapy Advisor

PLYMOUTH MEETING, Pa., April 15, 2021 /PRNewswire/ --Inovio (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focusing on the human immune responses induced by INOVIO's DNA vaccine candidate for COVID-19, INO-4800, against variants of concern. The results showed that INO-4800 induced a robust T cell response against all spike protein variants tested, which the company believes will be key in providing protection against SARS-CoV-2 variants, in addition to providing similar levels of neutralizing activity against both the UK and Brazilian variants as those against the original strain. The study, entitled "INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants," has been submitted for peer review and can be viewed at https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1.

Dr. J. Joseph Kim, INOVIO's President & CEO, said, "These results are consistent with our expectation that INO-4800, which was found to be well-tolerated and able to produce a balanced immune response in our Phase 1 trial, is able to generate both neutralizing antibodies and robust T cell responses both of which will be essential to protect against the emerging variants of concern."

Regarding INO-4800 development Dr. Kim said, "We will report Phase 2 results in 2Q, and, with FDA concurrence, expect to move into Phase 3 in the second quarter of this year. Our COVID vaccine's projected safety profile, its stability at room temperature for more than a year, and likely ability to safely boost numerous times positions INOVIO's COVID-19 vaccine as an important factor in addressing the virus in its pandemic and endemic states."

In the study, clinical samples were collected at varying timepoints post-immunization from subjects in INOVIO's Phase 1 US-based INO-4800 clinical trial. Antibodies capable of neutralizing activity were measured against the spike protein variants tested, including B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant). The study showed the T cell responses induced by INO-4800 vaccination were fully maintained against the UK, South African and Brazilian variants when compared to the T cell responses to the original Wuhan strain. The neutralization levels of INO-4800 against South Africa and UK variants were reduced to the levels similar to the previous reports of mRNA or viral vector vaccines. Furthermore, despite recent reports showing a reduction in neutralizing activity against the Brazilian variant by the mRNA or viral vector vaccines, INO-4800 generated robust neutralizing antibodies at levels against Brazilian variant which were comparable to those against the Wuhan strain. Taken together with the data showing the maintenance of T cell activity, the results reported in this study provide a comprehensive overview of cross-reactive cellular and humoral immune responses against SARS-CoV-2 variants for INO-4800 vaccinated individuals that may be important for protection against variant strains of SARS-CoV-2.

Collectively, the studies showcase how the combination of robust T cell responses in conjunction with neutralizing antibody responses provide an important defense against both emerging and potential future viral variants, exhibiting broad protection against the virus and less impacted by the mutational changes a virus may undergo.

About INO-4800

INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. Composed of an optimized DNA plasmid, INO-4800 is delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INO-4800 is the only nucleic-acid based vaccine that is stable at room temperature for more than a year, at 37o C for more than a month, has a five-year projected shelf life at normal refrigeration temperature and does not need to be frozen during transport or storage all of which are important considerations when preparing for mass immunizations.

About INOVIO's DNA Medicines Platform

INOVIO has 15 DNA medicine clinical programs currently in development focused on infectious diseases, cancer and HPV-associated diseases. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.

INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA. The CELLECTRA uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen, which is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require cold storage or transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials.

With more than 3,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, in the first of two Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV 16 and 18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a Phase 2 clinical trial in the U.S., as well as Phase 2 trials in China and South Korea. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DOD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit http://www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.comInvestors: Ben Matone, 484-362-0076, ben.matone@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines and in particular our clinical work relating to INO-4800 and its potential effectiveness against SARS-CoV-2 variants, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical trials and the availability and timing of data from those studies and trials, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

View original content:http://www.prnewswire.com/news-releases/inovios-covid-19-vaccine-candidate-ino-4800-provides-broad-cross-reactive-immune-responses-in-humans-against-variants-of-concern-301269572.html

SOURCE INOVIO Pharmaceuticals, Inc.

Read more here:

INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern - BioSpace